Drug intelligence / Profile preview

IMC-2015

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Parenteral

Overview

IMC-2015 is an investigational stem cell therapy being developed by ImmuneCyte Life Sciences for the treatment of Avascular Necrosis (AVN). The therapy is produced using the company's proprietary AutoSTEM platform, which is an automated system for the standardized isolation and expansion of stem cells. IMC-2015 aims to promote bone regeneration and revascularization in patients with AVN, a condition characterized by the death of bone tissue due to a lack of blood supply. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on IMC-2015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-2015.

Explore the full profile